中国批准首种本土药物 " Pegbing " 用于慢性乙型肝炎的功能治疗。 China approves first homegrown drug, Pegbing, for functional cure of chronic hepatitis B.

国家医疗产品管理局(National Medical Products Development Agency)表示, 中国已批准将百草枯(Pegbing)作为世界上首例针对慢性乙型肝炎的功能治疗, China has approved Pegbing, a homegrown injectable drug by Amoytop Biotech, as the world’s first treatment targeting a functional cure for chronic hepatitis B, the National Medical Products Administration said. 它设计用于抗病毒疗法,能够在治疗结束后持续清除乙型肝炎表面抗原,这是在没有终生药物的情况下实现长期缓解的关键一步。 Designed to be used with antiviral therapy, it enables sustained clearance of the hepatitis B surface antigen after treatment ends, a key step toward long-term remission without lifelong medication. 这一转变标志着全球乙型肝炎工作的一个重要里程碑,这一疾病影响到全世界2.54亿人,每年造成100多万人死亡,包括中国7 500万例。 The move marks a major milestone in global hepatitis B efforts, with the disease affecting 254 million people worldwide and causing over a million deaths annually, including 75 million cases in China. 中国在生物医学创新中的作用在不断提升。 The approval highlights China’s rising role in biomedical innovation.